261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Details

Database :

OAIster

Publication Type :

Electronic Resource

Accession number :

edsoai.on1456028636

Document Type :

Electronic Resource